Edition:
United Kingdom

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

11.04USD
9:00pm BST
Change (% chg)

$-0.16 (-1.43%)
Prev Close
$11.20
Open
$11.05
Day's High
$11.27
Day's Low
$10.82
Volume
330,884
Avg. Vol
298,835
52-wk High
$20.85
52-wk Low
$9.51

Latest Key Developments (Source: Significant Developments)

Alder Biopharmaceuticals Q1 Loss Per Share $1.63
Thursday, 2 May 2019 

Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS® REPORTS FIRST QUARTER 2019 FINANCIAL AND OPERATING RESULTS.Q1 LOSS PER SHARE $1.63.Q1 EARNINGS PER SHARE ESTIMATE $-1.03 -- REFINITIV IBES DATA.FDA SETS EPTINEZUMAB PDUFA DATE OF FEBRUARY 21, 2020; LAUNCH EXPECTED IN Q1 OF 2020.PLAN TO INITIATE A PHASE 3 CLINICAL TRIAL OF EPTINEZUMAB FOR ACUTE TREATMENT OF MIGRAINE IN SECOND HALF OF 2019.ALDER BIOPHARMACEUTICALS - CONTINUES TO EXPECT FY 2019 NET CASH USED IN OPERATING ACTIVITIES, PURCHASES OF PROPERTY&EQUIPMENT TO BE $285 TO $315 MILLION.  Full Article

Alder Biopharmaceuticals- Entered Distribution Deal To Offer, Sell From Time To Time Up To $100 Mln Maximum Aggregate Offering Price Of Shares
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS- ENTERED DISTRIBUTION DEAL TO OFFER, SELL FROM TIME TO TIME UP TO $100 MILLION MAXIMUM AGGREGATE OFFERING PRICE OF SHARES.  Full Article

Alder Biopharmaceuticals Q3 Loss Per Share $0.91
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS® REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS.Q3 LOSS PER SHARE $0.91.Q3 EARNINGS PER SHARE VIEW $-1.09 -- THOMSON REUTERS I/B/E/S.ALDER BIOPHARMA - BELIEVES CASH, CASH EQUIVALENTS, INVESTMENTS, RESTRICTED CASH WILL BE SUFFICIENT TO MEET PROJECTED OPERATING REQUIREMENTS INTO 2020.AS OF SEPTEMBER 30, 2018, ALDER HAD $484.7 MILLION IN CASH, CASH EQUIVALENTS, INVESTMENTS AND RESTRICTED CASH.  Full Article

Alder Biopharma Q4 Loss Per Share $0.80
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS.Q4 LOSS PER SHARE $0.80.‍BIOLOGICS LICENSE APPLICATION (BLA) ON TRACK FOR SUBMISSION IN 2H18​.  Full Article

Alder Announces $250 Million Committed Equity Financing
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES $250 MILLION COMMITTED EQUITY FINANCING.ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT.ALDER BIOPHARMACEUTICALS INC - TO USE NET PROCEEDS TO FUND PAYMENTS UNDER ALDER'S EUROPEAN PATENT SETTLEMENT.ALDER BIOPHARMACEUTICALS INC - TO ALSO USE PROCEEDS FOR EPTINEZUMAB INFUSION COMMERCIALIZATION-READINESS ACTIVITIES.  Full Article

Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY.ALDER BIOPHARMACEUTICALS INC - ‍ALDER HAS AGREED TO MAKE AN IMMEDIATE ONE-TIME PAYMENT OF $25 MILLION TO TEVA​.ALDER BIOPHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ALDER HAS AGREED TO WITHDRAW ITS APPEAL BEFORE EUROPEAN PATENT OFFICE.ALDER BIOPHARMACEUTICALS - UNDER TERMS CO AGREED TO PAY $75 MILLION AT EACH OF TWO SALES-RELATED MILESTONES FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER SAYS UNDER TERMS CO AGREED TO PROVIDE CERTAIN ROYALTY PAYMENTS ON NET SALES AT RATES FROM 5% TO 7% FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER - UNDER TERMS CO AGREED TO MAKE SECOND ONE-TIME PAYMENT OF $25 MILLION UPON APPROVAL OF BLA FOR EPTINEZUMAB WITH U.S. FDA.  Full Article

Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION.ALDER BIOPHARMACEUTICALS INC - ANNOUNCED THAT EPTINEZUMAB, MET PRIMARY ENDPOINT IN ITS PIVOTAL PHASE 3 PROMISE 2 CLINICAL TRIAL.ALDER BIOPHARMACEUTICALS INC - ‍15% OF PATIENTS HAD NO MIGRAINES FOR A FULL THREE MONTHS​.ALDER BIOPHARMACEUTICALS INC - IN ADDITION, EPTINEZUMAB MET ALL KEY SECONDARY ENDPOINTS WITH VERY HIGH STATISTICAL SIGNIFICANCE.ALDER BIOPHARMACEUTICALS INC - ‍SAFETY AND TOLERABILITY WERE SIMILAR TO PREVIOUSLY REPORTED EPTINEZUMAB STUDIES​.ALDER BIOPHARMACEUTICALS INC - PLANS TO SUBMIT A BLA TO U.S. FDA FOR EPTINEZUMAB IN H2 OF 2018.  Full Article

Alder Biopharmaceuticals Q3 loss per share $0.92
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals announces third quarter 2017 financial and operating results.Q3 loss per share $0.92.Q3 earnings per share view $-1.17 -- Thomson Reuters I/B/E/S.Alder Biopharmaceuticals Inc - ‍eptinezumab biologics license application (BLA) submission on track for 2h18​.Alder Biopharmaceuticals Inc - ‍promise 2 pivotal trial completed enrollment and top-line data on track for 1h18​.Alder-Sees available cash & cash equivalents, short-term investments to be sufficient for projected requirements through late 2018/early 2019​‍​.  Full Article

Alder Biopharmaceuticals Q2 loss per share $1.48
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals announces second quarter 2017 financial and operating results.Q2 loss per share $1.48.Q2 earnings per share view $-1.61 -- Thomson Reuters I/B/E/S.  Full Article

Alder Biopharmaceuticals says public offering of 15 mln common shares priced at $10 per share
Wednesday, 12 Jul 2017 

July 12 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals, inc. Prices public offering of common stock.Says public offering of 15.0 million common shares priced at $10.00per share.  Full Article

UPDATE 3-Novartis, Amgen in dispute over migraine drug partnership

NEW YORK/LOS ANGELES, April 4 Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.